Fierce Biotech Week brings together the industry’s top innovators, decision-makers, and visionaries driving the future of drug development, clinical research, business development and licensing, TMF, ...

Biotech interviews in 2026 demand more than just lab expertise—they assess critical thinking, communication, and the ability to operate within regulatory and fast-paced environments. Employers seek ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.

Alan H. Auerbach has served as Chairman of the Board and as CEO and President of Puma Biotechnology, Inc. since its inception. Before joining Puma, Mr. Auerbach served as Founder, CEO, President and a ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

Switzerland's biotech industry shifted toward private financing in 2025 as funding from capital markets remained difficult to obtain ​and pharmaceutical companies sought out collaborative ...